Xenon Pharmaceuticals XENE Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Xenon Pharmaceuticals (XENE) reported comprehensive income (loss), net of tax, attributable to parent of -$103.85M in Q1 2026.
- How has Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 61.6% year-over-year, from -$64.27M to -$103.85M.
- What is the long-term trend for Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 39.3% compound annual growth rate (CAGR), from -$127.38M to -$343.96M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a broader view of the company's financial performance by including items that bypass the traditional income statement. Investors use this to evaluate the overall change in the company's net worth during a reporting period.